疫苗预防中耳炎的研究进展与挑战
本文综述了2011年7月至2015年6月PubMed中关于中耳炎(OM)疫苗有效性和候选抗原开发的文献。肺炎球菌结合疫苗(PCVs)对肺炎球菌性OM、复发性OM、OM就诊和鼓膜置管有一定效果,但广泛使用导致血清型替换和病原菌变化,减弱了PCV对急性中耳炎(AOM)的效果。含流感嗜血杆菌蛋白D的10价肺炎球菌疫苗(PHiD-CV)对肺炎球菌性OM有效,但对流感嗜血杆菌所致OM的影响研究结果不一致。针对流感嗜血杆菌、卡他莫拉菌和OM相关呼吸道病毒的疫苗开发进展有限。
要点
- PCVs对肺炎球菌性OM、复发性OM、OM就诊和鼓膜置管有一定效果。
- PCVs广泛使用后肺炎球菌血清型和OM相关细菌病原体发生替换,减弱PCV对AOM的效果。
- PHiD-CV对肺炎球菌性OM有效,但对流感嗜血杆菌所致OM影响的研究结果不一致。
核心结论
- PCVs对肺炎球菌性OM、复发性OM、OM就诊和鼓膜置管有一定效果。
- PCVs广泛使用与肺炎球菌血清型和OM相关细菌病原体变化相关,减弱PCV对AOM的效果。
- PHiD-CV对肺炎球菌性OM有效,但描述对流感嗜血杆菌所致OM潜在影响的研究结果不一致。
- 针对流感嗜血杆菌、卡他莫拉菌和OM相关呼吸道病毒的疫苗开发进展有限。
- 需要更多研究将疫苗保护扩展至更多肺炎球菌血清型和其他致OM病原体。
研究设计与样本
- 在PubMed数据库检索OM病原体和候选疫苗抗原文献,限制为2011年7月至2015年6月发表的英文文章。
- 专家组成员审阅各自专业领域的文献。
主要发现
- PCVs对肺炎球菌性OM、复发性OM、OM就诊和鼓膜置管有一定效果。
- PCVs广泛使用与肺炎球菌血清型和OM相关细菌病原体变化相关,减弱PCV对AOM的效果。
- PHiD-CV对肺炎球菌性OM有效,但描述对流感嗜血杆菌所致OM潜在影响的研究结果不一致。
- 针对流感嗜血杆菌、卡他莫拉菌和OM相关呼吸道病毒的疫苗开发进展有限。
关键数值与推荐
- 文献检索限制为2011年7月至2015年6月发表的英文文章。
临床怎么用
- OM在全球范围内仍是重要的医疗负担,预防优于治疗,疫苗开发仍是重要目标。
- OM作为一种多种微生物疾病,给疫苗开发带来重大但并非不可克服的挑战。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective To review the literature on progress regarding (1) effectiveness of vaccines for prevention of otitis media (OM) and (2) development of vaccine antigens for OM bacterial and viral pathogens. Data Sources PubMed database of the National Library of Science. Review Methods We performed literature searches in PubMed for OM pathogens and candidate vaccine antigens, and we restricted the searches to articles in English that were published between July 2011 and June 2015. Panel members reviewed literature in their area of expertise. Conclusions Pneumococcal conjugate vaccines (PCVs) are somewhat effective for the prevention of pneumococcal OM, recurrent OM, OM visits, and tympanostomy tube insertions. Widespread use of PCVs has been associated with shifts in pneumococcal serotypes and bacterial pathogens associated with OM, diminishing PCV effectiveness against AOM. The 10-valent pneumococcal vaccine containing Haemophilus influenzae protein D (PHiD-CV) is effective for pneumococcal OM, but results from studies describing the potential impact on OM due to H influenzae have been inconsistent. Progress in vaccine development for H influenzae, Moraxella catarrhalis, and OM-associated respiratory viruses has been limited. Additional research is needed to extend vaccine protection to additional pneumococcal serotypes and other otopathogens. There are likely to be licensure challenges for protein-based vaccines, and data on correlates of protection for OM vaccine antigens are urgently needed. Implications for Practice OM continues to be a significant health care burden globally. Prevention is preferable to treatment, and vaccine development remains an important goal. As a polymicrobial disease, OM poses significant but not insurmountable challenges for vaccine development.
引用
- Pettigrew MM, Alderson MR, Bakaletz LO, et al. Panel 6: Vaccines. Otolaryngol Head Neck Surg. 2017. PMID: 28372533. doi:10.1177/0194599816632178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。